
Japan follows UK in GSK's comeback tour for Blenrep
The revitalisation of GSK's blood cancer therapy Blenrep has continued with a second regulatory approval, in Japan, as a treatment for multiple myeloma. The Ministry of Health, Labour and Welfare (MHLW) has cleared the BCMA-targeting antibody-drug …